Today, Friday, March 14, is World Sleep Day 2025, and this year’s theme is: Make Sleep Health a Priority. This day marks an opportunity to promote sleep health alongside thousands of sleep professionals and advocates. DocWire News spoke with our very own sleep professional, Dr. Anne Marie Morse, about the significance and theme of this year’s World Sleep Day and why sleep health matters for us all.
Advertisement
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
The American Kidney Fund's Living Donor Report Card found that many US states lack protections for living kidney donors.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
Dr. John Fruehauf details how novel therapies have improved the landscape of metastatic melanoma care.
A new innovation center in Boston will serve as Roche's cardiovascular, renal, and metabolism research and development hub.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
Advertisement
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
The Latest From Heme Today
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
CTD402 will enter a single-arm, open-label, phase 1b/2 trial aimed to optimize dosing and accelerate clinical development.
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.